（LenacapavirTablets）口服给药方式为预防方案提供多样化选择，便于快速启动干预。而且，来那帕韦 注射液采用皮下注射的给药方式，极大地提升了用药的便利性和依从性，为难以坚持每日服药的人群提 供了强有力的防护新手段。 近日，长效HIV暴露前预防（PrEP）药物来那帕韦（Lenacapavir）在博鳌一龄完成应用，为国内有需要 的人群提供"一年仅需两次给药"的HIV防护新选择。 来那帕韦（Lenacapavir）作为HIV-1衣壳抑制剂，凭借独特的作用机制，能有效降低通过性行为感染 HIV-1的风险，为HIV-1预防带来突破性进展。适用于有感染HIV-1风险的成人和体重不小于35kg的青少 年进行暴露前预防，以降低通过性行为感染HIV-1的风险（个体必须为HIV-1阴性才可以启动治疗）。 同时，来那帕韦"双剂型"的协同作用，开创了HIV预防新模式——来那帕韦注射液 （LenacapavirInjection）是仅需一年两次给药（每6个月注射一次）的长效药物；来那帕韦片 ...

Group 1: E-commerce and Trade - Alibaba International Station has seen a 42% year-on-year increase in platform orders since June, with GMV maintaining a strong growth of nearly 30% [1] - The U.S. market has recovered with a 25% growth rate, and there is a surge in early Christmas stocking up, while Europe continues to experience rapid growth [1] - Alibaba International Station is extending its "Foreign Trade 618" event in the U.S. market until August to help merchants capture the influx of U.S. orders [1] Group 2: Company Developments - Nichiha Precision Machinery announced that its wholly-owned subsidiary, Italy's MCM, will file for bankruptcy due to ongoing losses and inability to repay debts, but this will not significantly impact the company's domestic operations [2] - Gilead Sciences announced that the FDA has approved Yeztugo® as the first and only PrEP option in the U.S. requiring only two doses per year, significantly reducing the risk of HIV infection [5] - Kefu Medical, Wisdom Eye, and Laolai Health have signed a strategic cooperation agreement to develop AI-driven portable/home medical terminals focusing on chronic disease monitoring and emergency alerts [6] Group 3: Investment and Financing - EDGNEX, a digital infrastructure company based in Dubai, plans to invest $2.3 billion to build a large data center in Indonesia, with the first phase expected to be completed by 2026 [8] - Yuzhu Technology has completed its C-round financing led by several major investors, including Tencent and Alibaba, with most existing shareholders participating in the follow-up investment [8] - Ningbo Ocean plans to invest no more than 2 billion yuan to build four 4300TEU container ships, with funding sources including self-owned and self-raised funds [8] Group 4: Media and Entertainment - Disney China has partnered with Shanghai Animation Film Studio to launch a series of animated promotional shorts based on "Zootopia," utilizing various traditional Chinese animation techniques [3] - Bilibili has introduced a support policy for animated short dramas, offering cost coverage of 30% to 100% and revenue sharing of up to 80%, with significant growth in content consumption [4] Group 5: Technology and Innovation - Yausu Technology and Pfizer have developed an AI pathology recognition system that can accurately identify and quantify pancreatic tissue structures, significantly reducing the time required for manual annotation [10]

Core Viewpoint - Gilead's HIV-1 capsid inhibitor, Yeztugo (lenacapavir), has been approved by the FDA as a pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in adults and adolescents weighing at least 35 kg, marking a significant advancement in HIV prevention strategies [1][2]. Group 1: Drug Approval and Efficacy - Yeztugo is the first HIV prevention drug that requires administration only twice a year [2]. - In clinical trials (PURPOSE 1 and PURPOSE 2), over 99.9% of participants maintained an HIV-negative status, with PURPOSE 1 showing a 100% reduction in infection rates among cisgender women and PURPOSE 2 showing a 99.9% reduction among men who have sex with men, transgender men, transgender women, and non-binary individuals [2]. Group 2: Mechanism of Action - Lenacapavir works by binding directly to the HIV capsid protein subunits, regulating the stability and transport of the capsid, thereby preventing HIV from entering human cells and inhibiting multiple critical steps in the viral lifecycle [2][3]. - This multi-stage mechanism distinguishes lenacapavir from other approved antiretroviral drugs and shows no known cross-resistance with existing medications [2]. Group 3: Market Context and Future Implications - Prior to this approval, lenacapavir had not been authorized for pre-exposure prophylaxis in other countries, although it had been approved for treating multi-drug resistant HIV in the EU and the US [3]. - The introduction of a biannual dosing regimen could significantly improve adherence among high-risk populations who struggle with daily medication, potentially leading to a further decline in HIV prevalence if widely adopted [3].

Core Insights - The FDA has accepted Gilead Sciences' New Drug Application for lenacapavir, an injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis, with a target action date of June 19, 2025 [1] - Gilead's lenacapavir showed 100% efficacy in preventing HIV in cisgender women during the Phase 3 PURPOSE 1 trial, leading to a recommendation to offer the drug to all trial participants [2] - Gilead's stock has increased by approximately 74% since June of the previous year and around 21% year-to-date [3] Company Performance - Gilead is experiencing a turnaround in its stock performance, currently trading at 13.3 times forward earnings, which is below the pharmaceutical industry average of 14 [4] - Concerns exist regarding Gilead's past performance, where a previous stock surge due to hepatitis C treatment success was followed by a decline as demand waned [5] - The company aims to increase U.S. PrEP users to over one million by 2030 to achieve $4 billion in annual sales, with over 400,000 Americans currently using PrEP [6] Market Position - Gilead's HIV drug Biktarvy is protected from generic competition until 2033, positioning the company favorably compared to others facing patent expirations [6] - HIV product sales increased by 6% year-over-year to $4.59 billion in Q1 2025, indicating strong market performance [7] - Potential reductions in federal funding for HIV prevention programs could impact market dynamics, as noted by industry experts [8]